Skip to Content


Medically reviewed by Last updated on Mar 10, 2019.


(rif AX i min)

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Xifaxan: 200 mg [contains edetate disodium]

Xifaxan: 550 mg

Brand Names: U.S.

  • Xifaxan

Pharmacologic Category

  • Rifamycin


Rifaximin inhibits bacterial RNA synthesis by binding to bacterial DNA-dependent RNA polymerase.



Traveler's diarrhea: Low

Hepatic encephalopathy: Increased absorption in patients with Child-Pugh class C compared with patients with Child-Pugh class A


Extensive, mainly by CYP3A


Feces (96.6% primarily as unchanged drug); urine (0.32%)

Time to Peak

Healthy subjects and ISB-D patients: ~1 hour

Half-Life Elimination

Healthy subjects: 5.6 hours; IBS-D patients: 6 hours

Protein Binding

Healthy subjects: 67.5%; Hepatic impairment: 62%

Special Populations: Hepatic Function Impairment

The mean AUC in patients with hepatic impairment of Child-Pugh class A, B, and C was 10-, 14-, and 21-fold higher, respectively, compared with that of healthy subjects.

Use: Labeled Indications

Hepatic encephalopathy: Reduction in the risk of overt hepatic encephalopathy recurrence in adults

Irritable bowel syndrome with diarrhea: Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults

Traveler's diarrhea: Treatment of traveler's diarrhea caused by noninvasive strains of E. coli in adults and pediatric patients ≥12 years of age

Limitations of use: Rifaximin should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea caused by pathogens other than E. coli.

Off Label Uses

Clostridioides (formerly Clostridium) difficile infection (second or subsequent recurrence)

Based on the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) guidelines for Clostridioides (formerly Clostridium) difficile infection, rifaximin, following a standard course of oral vancomycin therapy, is an adjunctive treatment option in patients with >1 recurrence of C. difficile infection.

Overt hepatic encephalopathy episodes (treatment)

Based on the American Association for the Study of Liver Diseases (AASLD) practice guideline for hepatic encephalopathy, rifaximin may be added to lactulose therapy for the treatment of episodes of overt hepatic encephalopathy.


Hypersensitivity to rifaximin, other rifamycin antibiotics, or any component of the formulation

Dosing: Adult

Note: The 200 mg tablet may not be available in some international markets; consult local product labeling for availability.

Clostridioides (formerly Clostridium) difficile infection (second or subsequent recurrence) (off-label use): Oral: 400 mg 3 times daily for 20 days; administer after a standard course of oral vancomycin (IDSA/SHEA [McDonald 2018])

Hepatic encephalopathy: Oral:

Reduction of overt hepatic encephalopathy recurrence: 550 mg 2 times daily. Note: Supporting clinical trial evaluated efficacy over 6-month treatment period.

Treatment of hepatic encephalopathy (off-label use): 400 mg every 8 hours for 5 to 10 days (Mas 2003)

Irritable bowel syndrome with diarrhea (IBS-D): Oral: 550 mg 3 times daily for 14 days; may be retreated up to 2 times with the same dosing regimen if symptoms recur.

Traveler's diarrhea: Oral: 200 mg 3 times daily for 3 days

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Diarrhea, travelers’: Oral: Note: Efficacy has not been established for the treatment of diarrhea due to pathogens other than E. coli, including C. jejuni, Shigella, and Salmonella; avoid use in diarrhea with fever or blood in the stool; consider alternative therapy if symptoms persist or worsen after 24 to 48 hours of treatment

Children 3 to 11 years: Limited data available: 100 mg 4 times daily for up to 5 days has been used in 38 children (age range: 3 to 8 years) to treat infectious diarrhea (Beseghi 1998; Frisari 1997)

Children ≥12 years and Adolescents: 200 mg 3 times daily for 3 days

Hepatic encephalopathy: Oral: Adolescents ≥18 years: Reduction of overt hepatic encephalopathy recurrence: 550 mg 2 times daily

Inflammatory bowel disease (IBD) (Crohn disease, ulcerative colitis): Limited data available: Oral: Children ≥8 years and Adolescents: 10 to 30 mg/kg/day in divided doses; maximum daily dose: 1200 mg/day. Dosing based on a retrospective experience of 23 pediatric patients (age range: 8 to 21 years) with IBD flare (Crohn disease, n=12; ulcerative colitis: n=11); patients received rifaximin 400 to 1200 mg/day (10 to 30 mg/kg/day); improvements in diarrhea and abdominal pain were reported within the first 4 weeks of therapy for the majority of patients (~74%), and within a week in some cases; higher total daily doses (1200 mg/day vs 400 mg/day) were associated with better symptom control (Muniyappa 2009).

Small intestinal bacterial overgrowth (SIBO) (eg, irritable bowel syndrome [IBS], chronic abdominal pain): Limited data available; efficacy results variable: Oral: Children ≥3 years and Adolescents: 200 mg 3 times daily, dosing based on prospective study of 50 pediatric patients with IBS (age range: 3 to 15 years); results showed 7 days of therapy resulted in improved symptoms and a reduction in bacterial overgrowth based on lactulose breath test (LBT) results (Scarpellini 2013); however, a double-blind placebo-controlled trial in pediatric patients (n=75 including 49 who received rifaximin, age range: 8 to 18 years) with chronic abdominal pain showed very low efficacy in normalizing LBT (20% response rate) and treating SIBO compared to placebo at a higher dose of 550 mg 3 times daily for 7 days (Collins 2011).

Extemporaneously Prepared

A 20 mg/mL oral suspension may be made using tablets. Crush six 200 mg tablets and reduce to a fine powder. Add 30 mL of a 1:1 mixture of Ora-Sweet® and Ora-Plus® or a 1:1 mixture of Ora-Sweet® SF and Ora-Plus®; mix well while adding the vehicle in geometric proportions to almost 60 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label "shake well". Stable 60 days at room temperature.

Cober MP, Johnson CE, Lee J, et al, "Stability of Extemporaneously Prepared Rifaximin Oral Suspensions," Am J Health Syst Pharm, 2010, 67(4):287-89.20133533


Oral: Administer with or without food.


Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Drug Interactions

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Monitor therapy

CycloSPORINE (Systemic): May increase the serum concentration of RifAXIMin. Monitor therapy

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Monitor therapy

P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of RifAXIMin. Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Consider therapy modification

Adverse Reactions

Frequency of adverse events generally higher following treatment for hepatic encephalopathy (HE). Percentages are presented for HE unless otherwise stated.


Cardiovascular: Peripheral edema (15%)

Central nervous system: Dizziness (13%), fatigue (12%)

Hepatic: Ascites (11%)

Gastrointestinal: Nausea (14%; irritable bowel syndrome with diarrhea 2% to 3%)

2% to 10%:

Central nervous system: Headache (travelers' diarrhea 10%), depression (7%)

Dermatological: Pruritus (9%), skin rash (5%)

Gastrointestinal: Abdominal pain (>2% to 9%), pseudomembranous colitis (<5%; travelers' diarrhea or irritable bowel syndrome with diarrhea <2%)

Hematologic & oncologic: Anemia (8%)

Hepatic: Increased serum ALT (irritable bowel syndrome with diarrhea 2%)

Neuromuscular & skeletal: Muscle spasm (9%), arthralgia (6%), increased creatine phosphokinase (<5%; travelers' diarrhea or irritable bowel syndrome with diarrhea <2%)

Respiratory: Nasopharyngitis (7%), dyspnea (6%), epistaxis (>2% to 5%)

Miscellaneous: Fever (6%)

All indications: <2%, postmarketing, and/or case reports: Anaphylaxis, angioedema, Clostridioides (formerly Clostridium) difficile-associated diarrhea, exfoliative dermatitis, flushing, hypersensitivity reaction, urticaria


Concerns related to adverse effects:

• Hypersensitivity: Hypersensitivity reactions (eg, exfoliative dermatitis, rash, urticaria, flushing, angioneurotic edema, pruritus, anaphylaxis) have occurred; these events have occurred as early as within 15 minutes of drug administration.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Disease-related concerns:

• Diarrhea: Appropriate use: Avoid use in diarrhea with fever and/or blood in the stool and in the treatment of diarrhea due to pathogens other than E. coli, including C. jejuni, Shigella, and Salmonella (efficacy has not been established). Consider alternative therapy if symptoms persist or worsen after 24 to 48 hours of treatment.

• Hepatic impairment: Efficacy for prevention of encephalopathy has not been established in patients with a Model for End-Stage Liver Disease (MELD) score >25; use caution in patients with severe hepatic impairment (Child-Pugh class C).

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Dosage form specific issues:

• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).

Other warnings/precautions:

• Appropriate use: Not for treatment of systemic infections; <1% is absorbed orally.

Monitoring Parameters

Hypersensitivity reactions, temperature, blood in stool, change in symptoms; monitor changes in mental status in hepatic encephalopathy

Pregnancy Considerations

Adverse events have been observed in some animal reproduction studies. Due to the limited oral absorption of rifaximin in patients with normal hepatic function, exposure to the fetus is expected to be low.

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience rhinitis, pharyngitis, muscle spasm, joint pain, headache, dizziness, abdominal pain, or nausea. Have patient report immediately to prescriber swelling of arms or legs, abdominal edema, severe loss of strength and energy, shortness of breath, depression, or signs of Clostridium difficile (C. diff)-associated diarrhea (abdominal pain or cramps, severe diarrhea or watery stools, or bloody stools) (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.